Myovant Recognizes Prostate Cancer Awareness Month with Educational Sponsorships and Online Campaign to Encourage Patients to Speak Up, Seek Support and Be Informed
September 16 2022 - 10:37AM
Myovant Sciences (NYSE: MYOV) today announced an
educational campaign to inspire prostate cancer patients to speak
up and seek support through authentic conversations, along with the
sponsorship of educational opportunities for patients, providers,
and caregivers during Prostate Cancer Awareness Month. Studies have
repeatedly shown that many patients lack the resources and
willingness to speak openly about their condition, and Prostate
Cancer Awareness month presents the opportunity to address these
findings through increased awareness and education.
Through the power of storytelling, Myovant launched “Myovant
Stories” on Myovant.com to shine a light on stigma, science and
community through videos, articles, and resources for patients and
healthcare professionals. It will play host to the new video series
“Men With Prostate Cancer Find Support” which illustrates how
valuable peer to peer support can be. The videos also link to
resources that provide listings of third-party directories for
prostate cancer support groups.
"Prostate cancer is the most commonly diagnosed cancer in men
worldwide, but patients often find it difficult to discuss their
disease,” said Dave Marek, Chief Executive Officer of Myovant
Sciences, Inc. “We believe this new initiative can encourage men
with prostate cancer to be more vocal and empower them throughout
their care journey.”
It is estimated that one in eight men will be diagnosed with
prostate cancer during their lifetime.1 Additionally, one in three
men diagnosed with prostate cancer are at risk for depression or
anxiety.2 To help respond to these conditions, “Men with Prostate
Cancer Find Support” reinforces the value of support by featuring
men recruited from support groups sharing their experiences in a
free-flowing conversation captured on video.
“My wife and I attended support groups early on and that was
instrumental because it helped us each understand what we were
facing,” said Dan Leonard of California, patient volunteer in the
Myovant video series. “Support is crucial for getting through this,
so count me in for anything I can do to encourage men and their
loved ones, who are faced with this challenge, to seek
support.”
Myovant is partnering with key organizations across prostate
cancer to advance care for men with this disease. In working to
address barriers to care and stigma, Myovant is sponsoring the 18th
Annual African American Prostate Cancer Disparity Summit series
from Prostate Health Education Network (PHEN) and a webinar from
the Prostate Cancer Impact Alliance (PCIA) to address the needs of
men who have sex with men.
Continuing with patient education throughout the year, Myovant
is sponsoring the Urology Care Foundation, the official foundation
of the American Urological Association, and its distribution
of a new Prostate Cancer Health Playbook, a patient guide to help
educate men and their families to navigate their prostate
health.
Myovant wishes to acknowledge our advocacy partners, and health
care providers for their commitment to helping patients. We would
like to extend our sincere gratitude to the men who shared their
stories in this video series to help other prostate cancer patients
find needed support. Myovant’s video series “Men With Prostate
Cancer Find Support” will be published on myovant.com and via
social media.
ABOUT PROSTATE CANCERWorldwide, prostate cancer
is the most commonly diagnosed cancer in men and the fourth leading
cause of cancer-related deaths.3 The American Cancer Society
estimates that there will be about 268,000 new cases of prostate
cancer in 2022.4
Prostate cancer is considered advanced when it has spread or
come back after initial treatment and may include biochemical
recurrence (rising prostate-specific antigen in the absence of
metastatic disease on imaging), locally advanced disease, or
metastatic disease. Front-line medical therapy for advanced
prostate cancer typically involves androgen deprivation therapy,
which reduces testosterone to very low levels, commonly referred to
as castrate levels (< 50 ng/dL). Luteinizing hormone-releasing
hormone (LHRH) receptor agonists, such as leuprolide acetate, are
depot injections and the current standard of care for androgen
deprivation therapy. However, LHRH receptor agonists may be
associated with mechanism-of-action limitations, including the
potentially detrimental initial surge in testosterone levels that
can exacerbate clinical symptoms, which is known as clinical or
hormonal flare, and delayed testosterone recovery after the drug is
discontinued.5
ABOUT MYOVANT SCIENCESMyovant
Sciences aspires to redefine care for women and for men
through purpose-driven science, empowering medicines, and
transformative advocacy. Founded in 2016, Myovant has
executed five successful Phase 3 clinical trials across oncology
and women’s health leading to three regulatory approvals by
the U.S. Food and Drug Administration (FDA) for men with
advanced prostate cancer, women with heavy menstrual bleeding
associated with uterine fibroids, and premenopausal women with
moderate to severe pain associated with endometriosis,
respectively. Myovant also has received regulatory
approvals by the European Commission (EC) and
the United Kingdom Medicines and Healthcare Products
Regulatory Agency (MHRA) for women with symptomatic uterine
fibroids and for men with advanced hormone-sensitive prostate
cancer. Myovant has a supplemental New Drug Application under
review with the FDA for updates to the United States Prescribing
Information (USPI) based on safety and efficacy data from the Phase
3 LIBERTY randomized withdrawal study (RWS) of MYFEMBREE in
premenopausal women with heavy menstrual bleeding due to uterine
fibroids for up to two years. Myovant also is conducting
a Phase 3 study to evaluate the prevention of pregnancy in women
with uterine fibroids or endometriosis. Myovant also is
developing MVT-602, an investigational oligopeptide kisspeptin-1
receptor agonist, which has completed a Phase 2a study for female
infertility as part of assisted reproduction. Sumitovant
Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Pharma Co.,
Ltd., is Myovant’s majority shareholder. For more information,
please visit www.myovant.com. Follow @Myovant on
Twitter and LinkedIn.
Myovant Sciences ContactsInvestor
Contact:Uneek MehraChief Financial and Business
OfficerMyovant Sciences, Inc.investors@myovant.com
Media Contact:Noelle Cloud DuganVice President,
Corporate CommunicationsMyovant Sciences, Inc.media@myovant.com
1 Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics,
2022. CA Cancer J Clin. 2022 Jan;72(1):7-33. doi:
10.3322/caac.21708. Epub 2022 Jan 12. PMID: 35020204.2 Downing, et
al. The Lancet Oncology. 2019.3 Leslie SW, et al. Prostate Cancer.
StatPearls Publishing 2022.4 Siegel RL, Miller KD, et al. CA Cancer
J Clin. 2022 Epub 2022 5 Thompson IM. Flare Associated with
LHRH-Agonist Therapy. Rev Urol. 2001;3 Suppl 3(Suppl 3):S10-4.
A video accompanying this announcement is available
at: https://www.globenewswire.com/NewsRoom/AttachmentNg/cadb4692-28e4-429d-b132-a2e087a0ba9c
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Jul 2023 to Jul 2024